

## WuXi, I-Mab collaborate to develop three bispecific antibodies

27 September 2018 | News

Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody Platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline.



WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing and I-Mab Biopharma, a biotech company focusing exclusively on innovative biologics in immuno-oncology and auto-immune diseases, have jointly announced that I-Mab has expanded strategic collaboration with WuXi Biologics and licensed proprietary WuXiBody Platform to develop three bispecific antibodies. WuXi Biologics will also be the exclusive partner to develop and manufacture these bispecifics.

Under the terms of the agreement, I-Mab has rights to use the proprietary WuXiBody Platform to research, develop and commercialize three bispecific antibodies generated from I-MAB's proprietary pipeline. WuXi Biologics will receive an upfront payment as well as development, regulatory and commercial milestone payments, and will be entitled to royalties based on global sales of these bispecific antibodies.